GVR Report cover Intravenous Immunoglobulin Market Size, Share & Trends Report

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Immunodeficiency Diseases, Hypogammaglobulinemia, CIDP), By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

  • Published Date: May 2022
  • Report ID: 978-1-68038-800-8
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Data: 2018 - 2020

Report Overview

The global intravenous immunoglobulin market size was valued at USD 11.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.3% from 2022 to 2030. The growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of intravenous immunoglobulin (IVIG) treatments, and rising use of off-label indications are the key drivers of the market. The rising number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations.

U.S. intravenous immunoglobulin market size, by application, 2020 - 2030 (USD Billion)

The global IVIG market is expanding rapidly because of an increasing number of patients with bleeding issues and an increasing number of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients. Furthermore, increased investment in the healthcare industry is assisting in the growth of the IVIG market. Additionally, the growing number of patients suffering from autoimmune illnesses and other pathological conditions is fueling market expansion for IVIG products.

The COVID-19 pandemic, which is currently in its last stages, is expected to drive the global market. According to a December 2020 research called "COVID-19 in patients with primary and secondary immunodeficiency: The U.K. experience, 70 percent of 100 people with symptomatic secondary immunodeficiency (SID), primary immunodeficiency (PID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus, and 59 percent were admitted to hospitals, with 8 percent dying. As a result, because immunocompromised people are more likely to get COVID-19, the market for intravenous immunoglobulin therapy is predicted to expand during the pandemic.

Aside from the economic crisis, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. An uncommon but deadly illness known as MIS-C (multi-system inflammatory syndrome) has been documented in numerous places among the younger population. Many medical professionals have been evaluating the efficacy of IVIG injection for COVID-19 patients. For instance, in April 2021, Grifols, S.A. a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients, which is expected to boost the market growth in the forecast period. 

According to the W.H.O, currently, there are over 50 different Primary Immune Deficiencies (PIDs) such as specific antibody deficiency and X-lined hypo-gamma-globulinemia. PIDs include 176 different types of rare hereditary disorders. According to the U.S. National Library of Medicine and National Institute of Health, approximately 6 million patients are suffering from PID worldwide. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies over the forecast period.

The demand for IVIG therapies for the treatment of acquired and primary immunodeficiency diseases is increasing as it is the most effective and the only available treatment option. Moreover, sedentary lifestyle habits, including consumption of saturated fats, salt, and sugars, less physical activities, and high alcohol consumption have led to an increase in the prevalence of these diseases. The rising prevalence of lifestyle-associated disorders such as obesity and antibody deficiency disorders is expected to fuel the growth.

According to NIH data, over 500,000 persons in the U.S. suffer from more than 200 distinct types of primary immunodeficiency diseases (PIDDs). The rising prevalence of primary and acquired immunodeficiency illnesses including AIDS and X-linked hypogammaglobulinemia is projected to increase the demand for immunoglobulin therapy during the forecast period.

Furthermore, the rising cost of IVIG therapy is projected to be a significant barrier to market expansion. Immunoglobulin infusions are typically given once every 3 to 4 weeks, and the therapy is ongoing around 12-16 sessions yearly. The estimated cost of IVIG is USD 73.89 per gram, with a total cost of USD 10,000 depending on the severity of the illness. Immunoglobulin replacement treatments are long-term therapies that typically last 6 months. As per the ABIM Foundation, the expense of IgG treatment therapy exceeds USD 30,000 a year.

Application Insights

In 2021, immunodeficiency diseases dominated the market with a revenue share of over 20.0% owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. Hence, the business is expected to witness steady growth in the coming years.

The chronic inflammatory demyelinating polyneuropathy segment held the second-largest share in 2021. It is usually found in patients with diabetes mellitus. The treatment of CIDP involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods. The associated benefits such as safety, minimally invasive, and user-friendly treatment option are contributing to the growth of the industry.

Hypogammaglobulinemia accounted for the third-largest revenue share in 2021. This can be attributed to the increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).

The Kawasaki disease segment is expected to witness lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years. Moreover, factors such as increasing patient awareness levels and rising incidence of antibody deficiency diseases are expected to boost the demand for IVIG therapy, consequentially driving the segment.

Distribution Channel Insights

The hospital pharmacy segment dominated the market with a revenue share of over 55.0% in 2021 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies.  Moreover, the growing incidence of primary immune deficiencies, hepatitis C, and other diseases has resulted in an increment in the number of hospitalizations worldwide, expanding the customer preference for hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies.

Global intravenous immunoglobulin market share, by distribution channel, 2021 (%)

The specialty pharmacy segment is anticipated to grow significantly during the forecast period as specialty pharmacies enable easy treatment at home. Specialty drugs are an important and dynamic part of the pharmacy business. As a result, the number of licensed specialty drugs is increasing rapidly, which is driving the specialty pharmacy segment during the forecast period. 

Regional Insights

North America dominated the overall market in 2021 with a revenue share of over 45.0%. The increasing level of awareness pertaining to products involved in the treatment of immunodeficiency diseases, rising inclination of clinicians towards these therapies, and growing healthcare expenditure are the key factors contributing to the market growth. Furthermore, the growing administration of IVIG therapies for the treatment of illness, the existence of established healthcare as well as research infrastructure, and the rapidly increasing number of product approvals from the U.S. FDA are some of the factors anticipated to contribute to the regional market growth.

Changing lifestyles and the rising geriatric population prone to chronic diseases are some of the factors contributing to the growth of this industry. In addition, increasing incidences of PID are expected to present this market with future growth opportunities. In the U.S., autoimmune illnesses are the third most prevalent cause of chronic illnesses. Since many autoimmune disorders are uncommon, the National Institutes of Health predicts that diseases affect between 5% and 8% of the U.S. population. Autoimmune illnesses are becoming more common for unclear causes. The number is expected to grow over the forecast period.

The Asia Pacific is anticipated to exhibit a lucrative growth rate over the forecast period as a consequence of the increasing awareness and potential opportunities for the adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies, coupled with a growing geriatric population. Other factors contributing to the growth of this business are emerging economies, growing healthcare spending, and the rapidly growing immunoglobulin market. In addition, rising incidences of immune disorders, awareness levels pertaining to intravenous and subcutaneous immunoglobulin therapies, and improving healthcare facilities are anticipated to fuel further growth in the near future.

Key Companies & Market Share Insights

This industry is witnessing a significant boost owing to the growing number of FDA approvals. Owing to this, a number of local and international players are investing in the IVIG business. For instance, in February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Market players are adopting various strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a greater share by increasing their market penetration. For instance, on 25 April 2022, Grifols S.A. completed its purchase of Biotest, a significant and transformative deal that will boost growth and innovation. Grifols' purchase of Biotest AG allows it to accelerate and extend its product range, boost patient access to plasma medicines, operate the biggest private European network of plasma facilities (87 sites), and boost revenue growth and margin development. In January 2022, for example, Argenx SE confirmed that Japan's Ministry of Health, Labour, and Welfare certified VYVGART intravenous infusion for the treatment of severe adult patients with generalized myasthenia gravis who do not respond adequately to steroids or non-steroidal immunosuppressive treatments. Some prominent players in the global intravenous immunoglobulin market include:

  • Biotest AG

  • Baxter International Inc.

  • Octapharma AG

  • LFB Biotechnologies

  • Grifols SA

  • CSL Behring

  • China Biologics Products Inc.

  • Kedrion Biopharma

  • BDI Pharma Inc.

Intravenous Immunoglobulin Market Report Scope 

Report Attribute

Details

Market size value in 2022

USD 12.0 billion

Revenue forecast in 2030

USD 21.1 billion

Growth rate

CAGR of 7.3% from 2022 to 2030

Base year for estimation

2021

Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Application, distribution channel, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; China; Japan; India; Brazil; Mexico; South Africa

 

Key companies profiled

 

Biotest AG; Baxter International Inc.; Octapharma AG; LFB Biotechnologies; Grifols SA; CSL Behring; China Biologics Products Inc.; Kedrion Biopharma; BDI Pharma Inc.

Customization scope

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options

 

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global intravenous immunoglobulin market report on the basis of application, distribution channel, and region:

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Hypogammaglobulinemia

    • CIDP

    • Immunodeficiency Diseases

    • Congenital AIDS

    • Chronic Lymphocytic Leukemia

    • Myasthenia Gravis

    • Multifocal Motor Neuropathy

    • ITP

    • Kawasaki Disease

    • Guillain-Barre Syndrome

    • Others

  • Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

    • Hospital Pharmacy

    • Specialty Pharmacy

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • Middle East and Africa

      • South Africa

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.